Firms' Internal Audits Will Continue To Be Exempt From FDA Inspection
This article was originally published in The Gray Sheet
Executive Summary
The Office of Compliance will continue its policy of exempting manufacturers' internal audits from review during the corrective and preventive actions portion of Quality Systems inspections, FDA GMP/Quality Systems Expert Kim Trautman said at an April 29 Food & Drug Law Institute videoconference.